ArticleMycopathologia2025
Coccidioides Fungemia in Central California: A 10-Years Experience.
Article in Mycopathologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoccidioides fungemia is an uncommon but severe manifestation of disseminated coccidioidomycosis, associated with high mortality. Despite high endemicity in California's San Joaquin Valley, recent data from this region are limited. This study aims to describe the clinical characteristics, risk factors, and outcomes of patients with Coccidioides fungemia at a Central California tertiary care center.
methodsWe conducted a retrospective review of patients diagnosed with Coccidioides fungemia between 2015 and 2025 at Community Regional Medical Centers (CRMC) in Fresno, California. Data were collected from microbiology database and medical charts, including demographics, clinical presentation, diagnostics, treatment, and outcomes. Cases were classified based on EORTC/MSG criteria for disseminated fungal infections.
resultsEleven patients with C. immitis fungemia were identified. The mean age was 40 years, and 64% were male. Risk factors included advanced HIV/AIDS (3), autoimmune disease requiring corticosteroids or immunosuppressants (4), diabetes with ESRD (1), chronic alcohol use (1) and pregnancy (1). One patient had no identifiable immunosuppressive condition. Miliary pulmonary involvement and extrapulmonary dissemination occurred in 64% of cases, with multiple organ involvement in more than half. All patients had positive cultures from additional sites, including respiratory, CSF, skin, peritoneal, and reproductive tissues. Routine blood cultures were positive in only 3 patients; the remainder required fungal-specific cultures. Time to culture positivity ranged from 5 to 27 days. Despite severe presentations, over half received initial fluconazole monotherapy, and none were treated with dual antifungal therapy. Overall mortality was 91%, with 50% dying within 7 days and 80% within 30 days of documented fungemia. Most cases (9/11) represented new-onset acute infections.
conclusionsCoccidioides fungemia remains a rare but ominous complication of disseminated coccidioidomycosis, even in highly endemic areas. It appears to reflect fulminant, acute infection with high fungal burden and multiorgan dissemination. The diagnostic delay associated with routine cultures and the underutilization of aggressive antifungal therapy may contribute to poor outcomes. Increased clinical vigilance, early use of fungal-specific diagnostics, and prompt initiation of amphotericin B based treatment may improve prognosis in high-risk populations.
Indexed as
Identifiers
40478371What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.